Every Form 4 that Applied DNA Sciences, Inc. (APDN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow APDN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APDN filings page.
Applied DNA Sciences (APDN): A director reported acquiring 22,511 shares of common stock at $0 on 10/17/2025 via a restricted stock unit grant. Following the transaction, the director beneficially owned 22,512 shares, held directly.
The award vests 100% 90 days from the grant date, indicating a short vesting schedule before settlement into shares.
Applied DNA Sciences reported a director equity grant on a Form 4. On 10/17/2025, the reporting person acquired 22,511 shares of common stock at a price of $0, reflecting an equity award. Following the transaction, the director beneficially owns 22,512 shares directly.
The filing notes the award relates to restricted stock units that vest 100% after 90 days from the grant date, indicating a short vesting schedule tied to service.
Applied DNA Sciences disclosed an insider equity award. On 10/17/2025, Chief Financial Officer Beth Jantzen acquired 18,691 shares reported as common stock at $0 per share, tied to a restricted stock unit grant. The filing states 100% of the RSUs vest 90 days from the grant date. Following this grant, her beneficial ownership stood at 18,694 shares, held directly.
Applied DNA Sciences reported an insider transaction on a Form 4. A director received 22,511 shares of common stock on 10/17/2025, listed with Transaction Code "A" at a price of $0.
Following this award, the reporting person beneficially owned 22,512 shares held directly. The filing notes the grant is in the form of restricted stock units that vest 100% after 90 days from the date of grant.
Applied DNA Sciences filed a Form 4 showing a director acquired 22,511 shares of common stock at $0 on 10/17/2025. Following the transaction, the director beneficially owns 22,512 shares, held directly. The filing notes that 100% of the related restricted stock units vest 90 days from the date of grant.
Applied DNA Sciences reported an insider equity change on a Form 4. A director acquired 18,691 shares of common stock on 10/17/2025 with a reported price of $0 (transaction code A). Following the transaction, the reporting person beneficially owns 18,694 shares, held directly.
The filing notes that 100% of the restricted stock units vest upon 90 days from the date of grant, indicating the award structure tied to service over a short vesting period.
Applied DNA Sciences reported an insider equity change. The Chief Executive Officer filed a Form 4 showing acquisition of 18,691 shares of common stock on 10/17/2025 at a price of $0, coded “A.” Following the transaction, the officer beneficially owned 18,695 shares, held directly.
The filing notes that 100% of the related restricted stock units vest 90 days from the date of grant.